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Abstract
Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface of several
leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated molecular patterns. The role
of TLR4 in the pathophysiology of several age-related diseases is also well recognized, such as prostate cancer (PCa). TLR4
polymorphisms have been related to PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not
been evaluated by any systematic reviews.
Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide association studies
analyzing this relationship and included only white population. Considering appropriate criteria, only nine studies were
analyzed in the meta-analysis, including 3,937 aggressive PCa and 7,382 controls.
Results: Using random effects model, no significant association was found in the ten TLR4 SNPs reported by at least four included
studies under any inheritance model (rs2737191, rs1927914, rs10759932, rs1927911, rs11536879, rs2149356, rs4986790,
rs11536889, rs7873784, and rs1554973). Pooled estimates from another ten TLR4 SNPs reported by three studies also showed no
significant association (rs10759930, rs10116253, rs11536869, rs5030717, rs4986791, rs11536897, rs1927906, rs913930, rs1927905,
and rs7045953). Meta-regression revealed that study type was not a significant source of between-study heterogeneity.
Conclusions: TLR4 polymorphisms were not significantly associated with the risk of aggressive PCa.
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Prostate cancer (PCa) is the most common malignancy since
1984, the most frequently diagnosed cancer, and the second
leading cause of cancer-related deaths in 2013 among men in the
USA [1]. The risk of PCa is related to family history, race, and
genetic factors. Several other causes have been associated with
PCa pathogenesis, including infectious agents, chronic non-
infectious inflammatory diseases, diet, environmental carcinogens,
imbalance of sex hormone, obesity, and urine reflux [2–4].
Chronic inflammation has been linked to the pathogenesis of PCa
in both epidemiologic studies and molecular pathology investiga-
tions [5,6]. In particular, several studies have suggested that
sexually transmitted infections may be a risk factor for PCa
through causing inflammation, even though not all the studies are
consistent [7,8]. Chronic inflammation seems to induce prostate
carcinogenesis and also promote neoplastic progression [9].
Furthermore, several pathways linking inflammation and PCa
have been identified: an intrinsic one driven by genetic events that
cause neoplasia, and an extrinsic one driven by inflammatory
conditions that predispose to cancer [9]. Among these, the
eicosanoid pathway activated by cyclooxygenase 2 (COX-2) has
been suggested to be involved in the pathogenesis of aggressive
PCa by a recent study [10]. COX-2 was over-expressed in PCa
tumors and the intensity of immunostaining was correlated with
prostate tumor grade [11]. Despite the available evidence on the
role of the inflammatory response in PCa onset and progression,
the association between genetic variants of innate immune genes
and the risk of aggressive PCa remains unclear.
Toll-like receptor 4 (TLR4) is an important pathogen recogni-
tion receptor involved in detection of lipopolysaccharide (LPS) of
Gram-negative bacteria and other exogenous or endogenous
ligands [12]. The TLR4 encoding gene is located on chromosome
9q32-q33. Through nuclear factor kappa B (NF-kB), TLR4
initiates the production of pro-inflammatory cytokines, such as
interleukin (IL)-1, IL-6 and tumor necrosis factor-a (TNF-a) [13].
TLR4 also mediates signaling related to tumor cell invasion,
survival, and metastasis in various cancers [14,15]. Its activity and
function seems to be modulated by genetic variations, principally
single nucleotide polymorphisms (SNPs). Mice with deficiency or
mutation of TLR4 had a weaker inflammatory immune response
to viral, bacterial [16,17], and protozoal [18] infections than that
of wild-type mice. Therefore, variations in TLR4 gene may modify
the signaling of the immune response, which in turn may have
effects on the pathogenesis of PCa.
Three recent meta-analyses have explored the association
between TLR4 SNPs and PCa [19–21]. They all reported non-
significant findings after stratification by ethnicity. However, these
studies focused their attention on overall PCa and did not contain
genome-wide association studies (GWASs). In addition, they did
not analyze the association between TLR4 SNPs and the
aggressive type of PCa. Thus, we conducted a systematic review
and meta-analysis of all genetic epidemiologic association studies
that have evaluated the relationship between TLR4 polymor-
phisms and risk of aggressive PCa. Both candidate-gene studies
and GWASs were included. The primary research questions are:
(1) is there an association between TLR4 SNPs and risk of
aggressive PCa and if so, what is the size of the relationship? (2)
what is the validity of the evidence of association between TLR4
polymorphisms and risk of aggressive PCa?
Materials and Methods
Ethics Statement
The execution of each individual study was previously approved
by the respective institution. This systematic review was performed
at the study level without access to individual-level data, and
therefore, institutional review board approval was not necessary.
Informed consent was obtained from each participant before the
start of each individual study.
Study Selection
The study was performed using pre-specified research objec-
tives, search strategy, study eligibility criteria, methods of data
extraction, and statistical analyses. Relevant studies were identified
by searching the MEDLINE (http://gateway.ovid.com/), EM-
BASE (http://www.embase.com), Science Citation Index (http://
science.thomsonreuters.com/cgi-bin/jrnlst/jlsearch.cgi?PC=K), and
Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.
gov/omim) databases for all genetic association studies published
before February 2013, using combinations of the search terms ‘‘toll-
like receptor 4,’’ OR ‘‘toll-like receptor 4 gene,’’ OR ‘‘TLR,’’ OR
‘‘TLR gene,’’ OR ‘‘TLR4,’’ OR ‘‘TLR4 gene,’’ AND ‘‘prostate
cancer,’’ OR ‘‘prostatic neoplasms.’’ GWASs were searched using
combinations of the search terms ‘‘genome-wide association study,’’
OR ‘‘GWAS,’’ AND ‘‘prostate cancer,’’ OR ‘‘prostatic neoplasms.’’
In addition, we manually searched the reference lists from reviews
and original articles to retrieve other papers relevant to the topic.
Where there was overlap in the study populations of published
papers, only the largest study was included. No language restriction
was placed on the literature search strategies. Unpublished findings
were not identified.
Exposure Measures
The main exposure variables were TLR4 genotypes as
measured in blood DNA samples from men in the respective
studies. This meta-analysis summarized TLR4 SNPs which were
reported by at least three included studies. Because many TLR4
SNPs were explored by two studies only, and the respective sample
sizes were small, these SNPs were not analyzed in this meta-
analysis.
Outcome Measures
The outcome measure was aggressive PCa as defined by
Gleason score greater than or equal to seven, or TNM stage
greater than or equal to T3b or any nodal involvement or any
distant metastases. However, some included studies extended this
definition. Controls for aggressive PCa are ideally men without
aggressive PCa chosen from the population at risk, although some
studies selected controls from men without screening for occult
PCa (Table 1).
Data Extraction
Three of us (PH Weng, YL Huang, and YC Chen) indepen-
dently reviewed each published paper and extracted relevant
information examining the associations between TLR4 polymor-
phisms and risk of aggressive PCa. Inter-observer differences, if
any existed, were reconciled through group discussion. In order to
pool data from different studies, we requested data from each
study based on the definition for aggressive PCa in this meta-
analysis, which may be slightly different from their original design.
For GWASs that did not report detailed information of TLR4,w e
contacted the investigators to obtain data on advanced PCa counts
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PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e110569and the corresponding TLR4 genotyping frequencies. To avoid
population stratification, this meta-analysis was restricted to
samples taken from European ancestry. We evaluated selection
bias based on the extent to which controls are representative of the
‘‘person-time population’’ from which the cases were sampled, and
the extent to which cases are a random sample of that latter
population.
Statistical Analyses
Meta-analyses were performed for SNPs that were reported by
at least three included studies. The pooled odds ratios (ORs) and
95% confidence intervals (CIs) for the associations between TLR4
genotypes and risk of aggressive PCa were calculated using
random effects models. Random effects models are preferred to
fixed effect models because of the differences in study designs and
study populations [22]. To incorporate both within-study and
between-study variability, we used DerSimonian and Laird’s [23]
random effects models to pool the estimates of log OR from each
individual study (unadjusted for covariates). Between-study
heterogeneity was quantified by using the I
2 statistic [24,25],
which indicates the proportion of variability across studies
attributable to heterogeneity. Tests of heterogeneity were assessed
by a x
2 statistic. To explore the inheritance mode for the effect of
TLR4 polymorphisms, we evaluated the following genotype
contrasts (where a and A denote minor and major alleles,
respectively): (1) a/a and A/a combined versus A/A (dominant
model); (2) a/a versus A/a and A/A combined (recessive model);
(3) a/a versus A/A and A/a versus A/A (co-dominant model); (4)
the increment of one minor allele (additive model). The Hardy-
Weinberg equilibrium (HWE) was assessed via x
2 test. We did not
perform haplotype analysis because none of the previous studies
performed haplotype analysis specific for these SNPs. Because
most GWASs did not adjust for covariates, this meta-analysis
reported unadjusted pooled results.
To evaluate the presence of publication bias, we examined the
funnel plot, by plotting the reciprocal of the standard error of log
OR versus the log OR, for symmetry. The Egger linear regression
test was also performed to assess funnel plot’s asymmetry [26].
Random effects meta-regression was performed under dominant
model to explore possible sources of between-study heterogeneity.
Study type (candidate-gene studies vs. GWASs) was the pre-
specified covariate. We did not perform stratification analysis
according to differences in control and case selection, because such
influences are complex and are usually not unidirectional. Because
previous studies revealed high concordance rate across genotyping
platforms [27], stratification analysis was not carried out according
to this covariate. Analyses were performed with Stata version 11.0
software (Stata Corporation, College Station, TX, USA). All P
values were two-sided. QUANTO program (http://hydra.usc.
edu/gxe/) was used to evaluate statistical power of the association
between TLR4 polymorphisms and aggressive PCa.
Results
Characteristics of Association Studies
Using the pre-specified search methodology we retrieved forty
relevant publications (Figure 1). After excluding duplicates
(n=10), seventeen studies were further excluded due to the
following reasons: (1) not European ancestry (n=5), (2) partially
overlapped populations (n=9), (3) lack of controls (n=1), and (4)
GWAS which did not include TLR4 gene (n=2).
We contacted the authors of the remaining 13 relevant studies
for necessary details, and authors of three of the GWASs [28–30]
didn’t respond and were thus excluded. One GWAS was excluded
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PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e110569because it didn’t contain the information of PCa aggressiveness
[31]. For studies composed of multiple cohorts (e.g., Lindstrom
et al. [32]), we tried to obtain data from each cohort and used the
original study to represent each cohort (e. g., Chen et al. [33] for
HPFS, Dunggan et al. [34] for CAPS, and Yeager et al. [35] for
PLCO). For the CAPS study, the GWAS by Dunggan et al. [34]
was selected instead of the candidate-gene study done by Zheng
et al. [36] because the former was composed of aggressive PCa
cases from Zheng’s study and evaluated more SNPs. In sum, nine
studies were included for the meta-analysis.
A total of 3,937 aggressive PCa cases and 7,382 controls were
included in this work. Six studies were candidate-gene studies
[33,37–41], and three of them were GWASs [34,35,42]. Six
papers studied US populations [33,35,37–39], one studied a
Swedish population [34], one studied the combination of UK and
Australian population [42], and one studied an Italian population
[40]. Details of the studies analyzed in this meta-analysis were
summarized in Table 1, including first author, year of publication,
type of study, ancestry, sample size, control selection, possible
sources of selection bias, definition of PCa aggressiveness,
genotyping methods and quality control.
For the association between TLR4 SNPs and aggressive PCa,
seven studies assessed rs4986790 [33–35,37,39,40,42]; five studies
investigated rs2149356 [33,34,37,39,41], rs11536889 [33,34,37,
39,41], rs7873784 [33,34,37,39,41]; and four studies explored
rs2737191[34,35,41,42], rs1927914 [33,34,38,39], rs10759932
[33,34,37,41], rs1927911 [33,34,38,39], rs11536879 [34,35,38,
42], and rs1554973 [34,35,41,42].
Allele Frequencies of TLR4 SNPs
Ten TLR4 SNPs had been evaluated by at least 4 included
studies. The minor allele frequencies (MAF) between case and
Figure 1. Study selection flowchart. Forty studies were reviewed after literature search. Among them, 31 studies were excluded due to
duplication, race other than whites, and insufficient data. A total of 9 studies were included for meta-analysis.
doi:10.1371/journal.pone.0110569.g001
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controls. Among them, three SNPs are located on 59 untranslated
region (UTR, rs2737191, rs1927914 and rs10759932), three are
intronic SNPs (rs1927911, rs11536879, and rs2149356), one is
non-synonymous exonic SNP (rs4986790), and three SNPs are
located on 39 UTR (rs11536889, rs7873784, and rs1554973).
Another 10 TLR4 SNPs were reported by 3 studies, including one
SNP located on the promoter region (rs10759930), one SNP
located on 59UTR (rs10116253), two intronic SNPs (rs11536869
and rs5030717), one non-synonymous exonic SNP (rs4986791),
and five SNPs located on 39 UTR (rs11536897, rs1927906,
rs913930, rs1927905, and rs7045953). The locations of the
explored SNPs (10 SNPs with $4 studies, 10 SNPs with 3 studies)
are shown in Figure 2. rs2149356, rs4986790 and rs7873784 in
Chen’s study and rs1927911 in Wang’s study were out of HWE
(P=0.01–0.03) but were kept in the analysis because the HWE
tests were not significant after correction for multiple tests.
Meta-Analysis
This meta-analysis was reported according to the PRISMA
checklist [43] (Checklist S1). Using random effects meta-analysis,
the ten TLR4 SNPs (rs2737191, rs1927914, rs10759932,
rs1927911, rs11536879, rs2149356, rs4986790, rs11536889,
rs7873784, and rs1444973) were not associated with the risk of
aggressive PCa regardless of the inheritance model used (Table 3,
Figure 3). The meta-analysis was also performed for another ten
SNPs which were reported by three included studies (rs10759930,
rs10116253, rs11536869, rs5030717, rs4986791, rs11536897,
rs1927906, rs913930, rs1927905, and rs7045953) (Table S1).
None of the SNPs revealed significant association with aggressive
PCa.
Publication Bias
Funnel plots were used to assess the relationship between the ten
TLR4 SNPs and aggressive PCa (Figure S1). Using the Egger
linear regression test, possible publication bias was found among
the included studies on rs1554973 (Egger test P=0.06). For the
other 9 SNPs, P values ranged from 0.2 to 0.77.
Meta-Regression
Random effects meta-regression was performed under domi-
nant model. Different study type (candidate-gene studies vs.
GWASs) was not a significant source of between-study heteroge-
neity (P value ranged from 0.15 to 0.79 for the ten TLR4 SNPs).
Power Calculation
For people of European ancestry, given a MAF of 0.15 and a of
0.05, this study had over 95% power to detect an OR of 1.20 for
3,937 cases and 7,382 controls.
Discussion
Recently, some researchers hypothesized that PCa is the result
of a chronic inflammatory process [44]. Proliferative inflammatory
atrophy (PIA), proposed as a potential precursor to PCa, occurs
frequently in the periphery of the prostate gland where PCa occurs
[5]. PIA lesions seem to be the result of different conditions,
including infections, chronic non-infectious inflammatory diseases,
dietary carcinogens, physical trauma, imbalance of sex hormone
and urine reflux [9]. Chronic infections may contribute to PIA and
lead to onset of PCa [45–47]. Several innate inflammatory
pathways seem to be involved. Among these, TLR4 pathway plays
a crucial role [48].
TLR4 recognizes pathogen-associated molecular patterns, i.e.
LPS [46]. Damage-associated molecular pattern molecules may
also interact with TLR4, i.e. oxidized low-density lipoprotein
(LDL) [49], one of the atherogenic lipoproteins associated with
atherosclerosis [50] and insulin resistance [51,52]. Their interac-
tion leads to the initiation of inflammatory response via NF-kB
(Figure 4) [53]. TLR4 can also promote PCa development
through releasing inflammatory mediators. Associations between
TLR4 SNPs and PCa have been examined in several studies,
though discordant data have been reported. However, the
relationship between TLR4 genotypes and aggressive PCa risk
has not been evaluated by any systematic reviews. Thus, we
performed a systematic review and meta-analysis of candidate-
gene studies and GWASs analyzing this relationship and restricted
to samples taken from European ancestry.
In the current meta-analysis, none of the examined TLR4 SNPs
was significantly associated with risk of aggressive PCa under any
inheritance model. No significant association was found between
the TLR4 SNPs (59UTR: rs2737191, rs1927914 and rs10759932;
intron: rs1927911, rs11536879, and rs2149356; exon: rs4986790;
39UTR: rs11536889, rs7873784, and rs1554973) and risk of
aggressive PCa in the pooled analysis. The non-significant findings
Figure 2. TLR4 SNPs evaluated in this meta-analysis. This plot was generated by the Locusview program. The highlighted boxed SNPs were
TLR4 polymorphisms explored by at least four studies. The remaining SNPs were those reported by three studies, discussed in the supplemental data.
doi:10.1371/journal.pone.0110569.g002
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PLOS ONE | www.plosone.org 9 October 2014 | Volume 9 | Issue 10 | e110569may be attributable to (1) failure to adjust for the conventional risk
factors of PCa, e.g. family history of PCa, (2) inability to assess the
within-population heterogeneity or geographic variation, and (3)
the studied TLR4 SNPs may be more closely related to non-
aggressive PCa.
Three recent meta-analyses evaluated the association between
TLR4 SNPs and overall PCa. Jing et al. [19], including four
candidate-gene studies [33,37,39,40], examined two TLR4 SNPs
(rs4986790 and rs4986791) and found that rs4986790 showed a
protective effect on overall PCa under co-dominant and recessive
models. However, the effect was not statistically significant after
stratification by ethnicity. Another work by Zhang et al. [20]
examined six TLR4 SNPs (rs1927914, rs4986790, rs4986791,
rs11536889, rs1927911, rs2149356) and did not find significant
associations with overall PCa. The pooled estimates of Zhang et al.
were derived from one Asian study [54] and four other
populations of European ancestry [33,36,39,41], which might be
confounded by population stratification. Zhu et al. [21] examined
rs4986790 and rs4986791 and found no significant association
with overall PCa in five populations of European ancestry
[33,36,37,39,40]. In summary, our findings on aggressive PCa
are consistent with the previous meta-analyses on overall PCa.
Our study had several advantages over the previous meta-analyses:
(1) this study additionally included GWASs, whereas previous
meta-analyses included candidate-gene studies only [19–21], (2)
this study focused on aggressive PCa, which is more clinically
relevant, (3) this study was restricted to populations of European
ancestry to avoid population stratification, and (4) this study
evaluated an additional 14 SNPs, which were not reported in the
previous meta-analyses.
Previous candidate-gene studies and GWASs found inconsistent
results for the association between TLR4 polymorphisms and PCa
risk. This may be explained by different ethnicity, within-
population heterogeneity, case and control selection, gene-gene
interactions, and gene-environment interactions. Although most of
the relevant medical centers were in the ‘‘catchment’’ area, Cheng
and colleagues [37] used controls from medical centers, which
Figure 3. Forest plot examines relationship between TLR4 SNPs and risk of aggressive prostate cancer. Odds ratios and weights were
demonstrated for each individual study and for the pooled analysis, assuming a dominant model. SNPs that were evaluated by at least 4 studies were
shown here.
doi:10.1371/journal.pone.0110569.g003
Figure 4. The role of TLR4 in innate immunity. TLR4 receptors are responsible for the recognition of bacterial lipopolysaccharide (LPS)
monomers and partially oxidized LDL (oLDL) on innate immune cells. LPS monomers and oLDL bind to sites on the protein, CD14. CD14 promotes the
binding of these ligands to the TLR4-MD-2 complex, which signals the activation of the nuclear factor kappa B (NF-kB) pathway. NF-kB products enter
the nucleus and result in transcription followed by the production of cytokines and the activation of multiple inflammatory pathways. This figure was
adapted from DeFranco et al. [48].
doi:10.1371/journal.pone.0110569.g004
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PLOS ONE | www.plosone.org 10 October 2014 | Volume 9 | Issue 10 | e110569differ from the source population in that not all men with potential
PCa would go to these centers to be screened and diagnosed.
There were some limitations of this study. One of them is the
possibility of publication bias. Though the funnel plots did not
reveal obvious publication bias among most of TLR4 SNPs, the
SNPs reported in this study were under the influence of
publication bias because only SNPs explored in $3 studies were
included. We were unable to include three other GWASs because
the authors did not respond to our data request [28–30]. After
exclusion of men with African and Asian ancestry, there was little
evidence that population stratification was a cause of confounding.
Though the included studies were conducted separately in the
United States, Sweden, Italy, UK and Australia, a prior theoretical
calculation on genetic case-control studies showed that ignoring
ethnicity among non-Hispanic U.S. Caucasians with ancestries
from different European countries resulted in bias of less than 1%
[55]. Last, the included studies used different genotyping
approaches, which may be associated with different genotyping
success rates and data quality. However, genotyping errors are
expected to be small, and thus the resulting biases are likely to be
small.
This study had some advantages. To the best of our knowledge,
this is the first meta-analysis on TLR4 polymorphisms and
aggressive PCa, which shows more clinical relevance. All the
included studies were reasonably well-designed epidemiological
studies. Genotyping was carried out ‘‘blind’’ to the disease status,
and assessment of aggressive PCa was carried out ‘‘blind’’ to the
genotypes. This study had sufficient power (.0.95) to detect a
potential OR of aggressive PCa associated with a SNP of 1.20.
This study presents the best available evidence on the relationship
between TLR4 polymorphisms and risk of aggressive PCa.
In conclusion, this study found that none of the examined TLR4
SNPs were significantly associated with risk of aggressive PCa
under any mode of inheritance. Control selection, different
ancestry, small statistical power in some studies, publication bias,
gene-gene and gene-environment interactions, different genotyp-
ing approaches, and issues of multiple tests may contribute to the
inconsistent findings in previous studies. Meta-regression revealed
that different study type (candidate-gene studies vs. GWASs) was
not a significant source of between-study heterogeneity. Large-
scale and well-designed studies using population-based controls
and more studies in each ethnic group are needed to confirm our
findings.
Supporting Information
Figure S1 Funnel plot of TLR4 SNPs. Funnel plot displays
the publication bias for each study (indicated as one dot) exploring
the relation between TLR4 SNPs and aggressive prostate cancer.
SNPs reported by at least four studies were shown here.
(TIF)
Table S1 Pooled estimated ORs and 95% CIs for the
association of TLR4 SNPs in aggressive PCa risk.
(DOC)
Checklist S1 PRISMA checklist.
(DOC)
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